Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Insulet stock soared out of a buy zone Friday after the insulin pump-maker "continued the beat-and-raise cadence it has seen in 2024." ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

A doctor and honorary researcher at the University of Exeter is leading a campaign to make reusable insulin pens the standard ...

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

Bernstein initiated coverage of Insulet (PODD) with an Outperform rating and $300 price target Innovation is driving accelerated insulin pump ...

Some diabetes patients this year have had trouble finding their preferred insulin brands as major drug manufacturers reported shortages of the medicine. USA TODAY set out to find out what patients ...

In our October research highlights, we look at a world-first stem cell transplant which helped a person with type 1 diabetes produce insulin, and how electrical impulses could regenerate cells in ...

Now, scientists have made a major breakthrough in developing what has been long called the “holy grail” diabetes treatments — a “smart” insulin that responds in real time to fluctuations in one’s ...

The U.S. Food and Drug Administration on Thursday announced a Class 1 recall for Medtronic MiniMed 600- and 700-series insulin pumps because of an increased risk of shorter battery life that could ...

WARSAW — Medtronic is notifying users of MiniMed 600 and 700 series insulin pumps of an increased risk for reduced battery life and less time until shutdown after a battery alert occurs. Pumps that ...